MST Access Investor Conference Presentation
MST Access Investor Conference Presentation
Race Oncology’s Mr Phil Lynch (CEO & MD) and Dr Daniel Tillett (CSO & ED) presented to the MST Access Australian Micro & Small Caps Conference 2021 on the 17th June 2021....
Race Executes Key Contract for Israel Phase 2 AML Trial
Race Executes Key Contract for Israel Phase 2 AML Trial
8 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed a contract with Trialog Clinical Trials Ltd, Israel, to support the coming combination Phase 2 Acute Myeloid Leukaemia trial....
CEO Phil Lynch Talks to the Australian Shareholder Association Podcast
CEO Phil Lynch Talks to the Australian Shareholder Association Podcast
Race CEO/MD Phillip Lynch speaks to the Australia Shareholders Association about Race Oncology and our Three Pillar strategy to commercialise Bisantrene....
MST Access initiates coverage of Race Oncology
MST Access initiates coverage of Race Oncology
MST Access has initiated coverage of Race Oncology with a current $4.88 per share valuation. The full report can be downloaded below....
Race leadership team strengthened
Race leadership team strengthened
1 September 2020 – Race Oncology Limited (ASX: RAC) is pleased to announce that it has expanded its executive team with the appointment of Mr Phil Lynch as Chief Executive Officer and Managing Director....
Race reports impressive 40% response in Phase II Bisantrene AML Trial
Race reports impressive 40% response in Phase II Bisantrene AML Trial
On 16 July 2020, Race was pleased to report results of the investigator led Phase II trial of bisantrene for relapsed or refractory Acute Myleoid Leukaemia. This post summarises the highlights and provides access...
Race starts preclinical breast cancer study for Bisantrene
Race starts preclinical breast cancer study for Bisantrene
Race Oncology is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle. Eminent cancer researcher, Associate Professor Nikki Verrills of the Hunter Medical Research Institute,...
Race raises A$1.8 million, appoints Non-Executive Chairman
Race raises A$1.8 million, appoints Non-Executive Chairman
Race has received firm commitments for A$1.8 million (before costs) in new equity funding via a strategic placement of six million ordinary shares, at an issue price of $0.30 per share. The placement has...
Race appoints Australian Clinical Program Director
Race appoints Australian Clinical Program Director
Race Oncology is pleased to welcome highly experienced oncology clinical trials specialist Dr Marinella Messina as its Australian Clinical Program Director. Dr Messina will commence of 16 March 2020 and will be responsible for...
Professor Borje Andersson appointed Director of Race
Professor Borje Andersson appointed Director of Race
Race Oncology Limited is pleased to announce that Professor Borje Andersson has been appointed to the Board as a Non-Executive Director. Prof Andersson is an internationally acclaimed leader in the fields of leukaemia and...
